179 related articles for article (PubMed ID: 38467790)
1. Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.
Vilaseca A; Farina A; Villagrán-García M; Pegat A; Benaiteau M; Ciano-Petersen NL; Do LD; Rogemond V; Gonçalves D; Psimaras D; Birzu C; Honnorat J; Joubert B
J Neurol; 2024 Jun; 271(6):3279-3290. PubMed ID: 38467790
[TBL] [Abstract][Full Text] [Related]
2. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor-associated central nervous system autoimmunity.
Valencia-Sanchez C; Sechi E; Dubey D; Flanagan EP; McKeon A; Pittock SJ; Zekeridou A
Eur J Neurol; 2023 Aug; 30(8):2418-2429. PubMed ID: 37151179
[TBL] [Abstract][Full Text] [Related]
4. Neurological complications of immune checkpoint inhibitor cancer immunotherapy.
Zivelonghi C; Zekeridou A
J Neurol Sci; 2021 May; 424():117424. PubMed ID: 33812689
[TBL] [Abstract][Full Text] [Related]
5. Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors.
Farina A; Villagrán-García M; Ciano-Petersen NL; Vogrig A; Muñiz-Castrillo S; Taillandier L; Michaud M; Lefilliatre M; Wang A; Lepine Z; Picard G; Wucher V; Dhairi M; Fabien N; Goncalves D; Rogemond V; Joubert B; Honnorat J
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36446613
[TBL] [Abstract][Full Text] [Related]
6. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study.
Fonseca E; Cabrera-Maqueda JM; Ruiz-García R; Naranjo L; Diaz-Pedroche C; Velasco R; Macias-Gómez A; Milisenda JC; Muñoz-Farjas E; Pascual-Goñi E; Gállego Perez-Larraya J; Saiz A; Dalmau J; Blanco Y; Graus F; Martinez-Hernandez E;
Lancet Neurol; 2023 Dec; 22(12):1150-1159. PubMed ID: 37977714
[TBL] [Abstract][Full Text] [Related]
7. Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma.
Möhn N; Sühs KW; Gingele S; Angela Y; Stangel M; Gutzmer R; Satzger I; Skripuletz T
Melanoma Res; 2019 Aug; 29(4):435-440. PubMed ID: 30855529
[TBL] [Abstract][Full Text] [Related]
8. Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
Rossi S; Gelsomino F; Rinaldi R; Muccioli L; Comito F; Di Federico A; De Giglio A; Lamberti G; Andrini E; Mollica V; D'Angelo R; Baccari F; Zenesini C; Madia P; Raschi E; Cortelli P; Ardizzoni A; Guarino M
J Neurol; 2023 Jun; 270(6):2975-2986. PubMed ID: 36800019
[TBL] [Abstract][Full Text] [Related]
9. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
[TBL] [Abstract][Full Text] [Related]
10. Dataset for: Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune-related adverse events.
Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
Data Brief; 2024 Apr; 53():110062. PubMed ID: 38317734
[TBL] [Abstract][Full Text] [Related]
11. Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes.
Sechi E; Markovic SN; McKeon A; Dubey D; Liewluck T; Lennon VA; Lopez-Chiriboga AS; Klein CJ; Mauermann M; Pittock SJ; Flanagan EP; Zekeridou A
Neurology; 2020 Oct; 95(17):e2442-e2452. PubMed ID: 32796130
[TBL] [Abstract][Full Text] [Related]
12. Central nervous system complications associated with immune checkpoint inhibitors.
Vogrig A; Muñiz-Castrillo S; Joubert B; Picard G; Rogemond V; Marchal C; Chiappa AM; Chanson E; Skowron F; Leblanc A; Ducray F; Honnorat J
J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):772-778. PubMed ID: 32312871
[TBL] [Abstract][Full Text] [Related]
13. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors.
Vogrig A; Fouret M; Joubert B; Picard G; Rogemond V; Pinto AL; Muñiz-Castrillo S; Roger M; Raimbourg J; Dayen C; Grignou L; Pallix-Guyot M; Lannoy J; Ducray F; Desestret V; Psimaras D; Honnorat J
Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31454760
[TBL] [Abstract][Full Text] [Related]
14. Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy.
Valencia-Sanchez C; Zekeridou A
Front Neurol; 2021; 12():642800. PubMed ID: 33897597
[TBL] [Abstract][Full Text] [Related]
15. Neurological autoimmunity in patients with non-pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles.
Mangioris G; Halfdanarson TR; Lennon VA; Chang BK; Dubey D; Dyck PJB; Flanagan EP; McKeon A; Mills JR; Pittock SJ; Zekeridou A
Eur J Neurol; 2024 Jun; 31(6):e16273. PubMed ID: 38466015
[TBL] [Abstract][Full Text] [Related]
16. CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review.
Khan E; Shrestha AK; Elkhooly M; Wilson H; Ebbert M; Srivastava S; Wen S; Rollins S; Sriwastava S
J Neurol Sci; 2022 Jan; 432():120089. PubMed ID: 34942546
[TBL] [Abstract][Full Text] [Related]
17. "Non-classical" paraneoplastic neurological syndromes associated with well-characterized antineuronal antibodies as compared to "classical" syndromes - More frequent than expected.
Berger B; Bischler P; Dersch R; Hottenrott T; Rauer S; Stich O
J Neurol Sci; 2015 May; 352(1-2):58-61. PubMed ID: 25824848
[TBL] [Abstract][Full Text] [Related]
18. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.
Diamanti L; Picca A; Bini P; Gastaldi M; Alfonsi E; Pichiecchio A; Rota E; Rudà R; Bruno F; Villani V; Galiè E; Vogrig A; Valente M; Zoccarato M; Poretto V; Giometto B; Cimminiello C; Del Vecchio M; Marchioni E
Neurol Sci; 2022 Mar; 43(3):2031-2041. PubMed ID: 34424427
[TBL] [Abstract][Full Text] [Related]
19. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity.
Farina A; Birzu C; Elsensohn MH; Picca A; Muñiz-Castrillo S; Vogrig A; Villagrán-García M; Ciano-Petersen NL; Massacesi L; Hervier B; Guégan S; Kramkimel N; Vano Y; Salem JE; Allenbach Y; Maisonobe T; Assaad S; Maureille A; Devic P; Weiss N; Pegat A; Maucort-Boulch D; Ricard D; Honnorat J; Psimaras D; Joubert B
Brain Commun; 2023; 5(3):fcad169. PubMed ID: 37389303
[TBL] [Abstract][Full Text] [Related]
20. Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition.
Ghosh N; Postow M; Zhu C; Jannat-Khah D; Li QZ; Vitone G; Chan KK; Bass AR
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
